Valganciclovir

Phase 3UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Cytomegalovirus Retinitis

Conditions

Cytomegalovirus Retinitis, HIV Infections

Trial Timeline

— → —

NCT ID

NCT00017784

About Valganciclovir

Valganciclovir is a phase 3 stage product being developed by Roche for Cytomegalovirus Retinitis. The current trial status is unknown. This product is registered under clinical trial identifier NCT00017784. Target conditions include Cytomegalovirus Retinitis, HIV Infections.

What happened to similar drugs?

7 of 20 similar drugs in Cytomegalovirus Retinitis were approved

Approved (7) Terminated (3) Active (10)

❌mRNA-1647ModernaPhase 3

🔄ASP0113 + PlaceboAstellas PharmaPhase 3

🔄Letermovir tablet + Letermovir IVMerckPhase 3

✅LetermovirMerckApproved

🔄Letermovir + PlaceboMerckPhase 3

🔄LetermovirMerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00002222	Pre-clinical	Completed	—	—	Cytomegalovirus Retinitis
NCT00017784	Phase 3	UNKNOWN	—	—	Cytomegalovirus Retinitis
NCT01663740	Approved	Completed	Jan 30, 2012	Dec 30, 2016	Cytomegalovirus Infections
NCT00361933	Approved	Withdrawn	Dec 1, 2008	May 1, 2009	Giant Lymph Node Hyperplasia
NCT00275314	Phase 3	Terminated	Feb 1, 2006	Apr 1, 2006	Kidney Transplant
NCT00227370	Phase 3	Completed	Jul 1, 2003	Dec 1, 2008	Cytomegalovirus Infections
NCT00374686	Pre-clinical	Completed	Mar 1, 2003	Sep 1, 2005	Cytomegalovirus Infection
NCT00275665	Phase 3	Completed	Nov 1, 2001	Jul 1, 2007	Bone Marrow Stem Cell Transplant

Competing Products

20 competing products in Cytomegalovirus Retinitis

See all competitors

Product	Company	Stage	Hype Score
mRNA-1273	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 3	0
ASP0113 + Placebo	Astellas Pharma	Phase 2	35
ASP0113 + Placebo	Astellas Pharma	Phase 3	40
Letermovir oral granules + Letermovir tablet + Letermovir intravenous	Merck	Phase 2	35
Letermovir 240 mg Oral Tablet	Merck	Phase 2	42
Letermovir tablet + Letermovir IV	Merck	Phase 3	40
Letermovir	Merck	Phase 1	36
Letermovir	Merck	Approved	43
Letermovir 480 MG [Prevymis]	Merck	Phase 2	42
V160 Low Dose IM + V160 Medium Dose IM + V160 High Dose IM + V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM + V160 High Dose plus MAPA 225 µg /dose IM + V160 Maximum Dose IM + V160 Medium Dose ID	Merck	Phase 1	29
Ganciclovir	Merck	Pre-clinical	26
Letermovir + Placebo	Merck	Phase 3	40